003850

Boryung is a South Korean pharmaceutical company that develops, manufactures, and markets prescription and over-the-counter medicines. Its business segments include chronic metabolic diseases, specialty care, central nervous system (CNS) disorders, oncology, and renal care. Key products include the Kanarb family for hypertension and dyslipidemia, Trulicity for diabetes, and the Taxotell global business acquired from Sanofi for breast cancer treatment. The company also offers OTC brands such as Gelphos and Yungaksan. Boryung operates manufacturing facilities in Ansan and Yeosu, with the latter holding EU-GMP certification. It serves domestic hospitals, clinics, and pharmacies, and is expanding into global markets through CDMO contracts and international business acquisitions. The company maintains R&D centers in Seoul and Gwanggyo, focusing on new drug development and improved formulations.

Summarised from the company's own disclosures, fiscal year ended Jul 2026

Industry Drug Manufacturers - General Homepage boryung.co.kr
Sector Healthcare IR page pharm.boryung.co.kr/ir
Tags
prescription drugs, over-the-counter drugs, oncology, diabetes, hypertension, renal care, cns disorders, cdmo, generic drugs, branded drugs, Kanarb, Dukarb, Tuvero, Akab, Dukarb Plus, Trulicity, Taxotell, Gelphos, Yungaksan, Yungaksan Cool, Gelphos M, Gelphos L, Zyprexa, Gemzar, Campto, Oxaliplatin, Zeloda, Onvevzi, Genxol, Dacxel, Sampnet, Velkin, Neulasta, Glasgin, L-family, L-Ong, L-Zero, L-Zero Jet
Press page —

Metrics

Valuation  
Market cap ₩ 779.898B
Market cap (USD) $ 573.991M
P/E 6.33
PEG 0.41
P/BV 0.87
P/S 0.74
P/OCF 5.19
P/FCF 6.22
Dividend yield —
Turnover / mcap —
Returns  
ROE 7.9%
ROI 7.6%
ROIC 7.1%
Profit margin 6.3%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 15.4%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 58.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 1.017T 1.017T 859.626B 760.476B 627.279B 561.867B 524.269B 460.402B 422.721B 409.14B 401.35B 359.491B 327.279B
Net profit 64.303B 69.633B 40.203B 41.894B 43.044B 26.856B 32.222B 20.307B 56.699B 5.614B 20.301B 21.591B 14.127B
Free cash flow 110.938B 67.732B 27.241B 7.538B 44.034B 26.47B -20.021B -15.914B -87.214B -15.708B 899.701M -6.521B 18.039B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 8.443K 10.145K — — — — — — — — — — —
Price performance 12m -0.17 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 136B 143B 131B 132B 114B 117B 144B 165B 194B 177B
↳ YoY growth +4.2% +5.6% -8.8% +1.2% -14.0% +2.8% +23.1% +14.3% +18.0% -9.0%
↳ 5y CAGR +5.6% +3.7% -2.7% -2.9% +0.1% +4.7% +8.0% +9.2%
Borrowings, current (KRW) 1.25B — — — — 25.8B 113B 50.6B — —
Borrowings, non-current (KRW) 0.00 — — — — 111B 94.2B 152B 124B 245B
Bonds payable (KRW) — — — — — — 78B — — 200B
Lease liabilities (KRW) — 0.00 0.00 384M 826M 757M 1.13B 1.9B 4.25B 18.9B
Cash and deposits (KRW) 26.3B 16.4B 7.62B 4.52B 25.5B 151B 16.1B 16.5B 187B 228B
Intangible assets (KRW) 17.8B 17.5B 17.4B 15.7B 55.7B 92.8B 184B 173B 155B 144B
Right-of-use assets (KRW) — — 0.00 891M 1.32B 747M 2.06B 2.67B 5.14B 19.4B
Net debt (borrowings + leases - cash) (KRW) -25.1B — — — — -13.1B 192B 188B -59.3B 35.9B
Cash flow detail
Operating cash flow (KRW) 9.36B -24.3B 38.9B 47B 44.7B 60.2B 27.8B 42.2B 80.6B 133B
Purchases of property, plant and equipment (KRW) -25.1B -63B -54.8B -67B -18.3B -16.1B -20.3B -15B -12.8B -22.2B
Purchases of intangible assets (KRW) -1.76B -4.08B -2.3B -1.73B -38.3B -43.2B -103B -8.33B -7.22B -7.7B
Change in inventories (cash effect) (KRW) -26.2B 7.65B — — — — — — — —
Change in payables (cash effect) (KRW) 15.3B -5.91B — — — — — — — —
Dividends paid (cash effect) (KRW) -1.56B -1.62B -6.8B -2.52B -4.2B -4.51B -6.59B -6.59B -6.77B -8.4B
Share buybacks (cash effect) (KRW) -5.13B -147M -5B 0.00 -5.83B -4.69B -188M 0.00 0.00 —
Interest paid (cash effect) (KRW) -824M -420M 0.00 0.00 -2.71B -4.23B -5.95B -9.32B -9.03B -10.4B
Income taxes paid (cash effect) (KRW) -8.82B -31.5B 862M -8.24B -14.3B -12B -22.1B -21.3B 5.24B -9.36B
Free cash flow (OCF - PPE - intangibles) (KRW) -17.5B -91.3B -18.2B -21.8B -11.9B 850M -95.2B 18.9B 60.5B 103B
Income detail
Research and development expense (KRW) — — — — — — 41.7B 47.3B 51.5B 65.1B
Total comprehensive income (KRW) 6.1B 55.9B 18.1B 29.4B 25.5B 44.4B 48.8B 37.3B 67.3B 69.8B
Comprehensive income to owners (KRW) 6.1B 56.1B 18.1B 29.4B 25.5B 44.3B 48.7B 37.3B 67.3B 69.8B
Provision for credit losses (KRW) -346M 3.98B — — — — — — — —
Credit cost ratio (credit losses / average receivables) (%) 0.3% 2.9% — — — — — — — —
Reported Mar 29, 2019 Mar 30, 2020 Aug 14, 2019 Mar 30, 2020 Mar 18, 2021 Mar 11, 2024 Mar 20, 2025 Mar 20, 2025 Mar 20, 2025 Jul 9, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

기타경영사항(자율공시) Bull 0 Bear 0 Routine
임시주주총회결과 Bull 0 Bear 0 Routine
주요사항보고서(자기주식처분결정) Bull 1 Bear 0 Capital return

Prompts

Boryung (ticker 003850), listed in South Korea.

ETFs Holding Boryung

ETF Weight in ETF Shares Market value As of
AVEE 0.01% 1,794 $ 11.73K Nov 16, 2026
DFEV 0.01% 21,171 $ 141.304K Nov 12, 2026
DFSE 0.00% 3,926 $ 26.204K Nov 12, 2026
DFEM 0.00% 46,198 $ 308.345K Nov 12, 2026
DFAE 0.00% 29,565 $ 197.33K Nov 12, 2026
DEXC 0.00% 743 $ 4,959.10 Nov 12, 2026
DFAX 0.00% 17,835 $ 119.039K Nov 12, 2026
AVEM 0.00% 67,616 $ 442.113K Nov 16, 2026
AVXC 0.00% 199 $ 1,301.18 Nov 16, 2026